A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
National Cancer Institute (NCI)
University of Vermont
Pfizer
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Swiss Cancer Institute
R-Pharm
Canadian Cancer Trials Group
University of California, San Diego
Bayer
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Radiation Therapy Oncology Group
University Health Network, Toronto
Cancer Trials Ireland
Amgen
Clovis Oncology, Inc.
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
AstraZeneca
GlaxoSmithKline
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Barbara Ann Karmanos Cancer Institute
Fox Chase Cancer Center
National Cancer Institute (NCI)